Venous thromboembolic complications are a major and often unrecognized cause of morbidity and mortality after acute ischaemic stroke. It has been reported that deep-vein thrombosis (DVT) occurs in 11-75% of patients, and pulmonary embolism (PE) in 3-39% (1) . Without thromboprophylaxis, DVT occurs in approximately 70% of patients and up to 2% of patients suffer a fatal PE (2) . Factors, such as old age and obesity, contribute to the overall risk of venous thromboembolism (3) (4) (5) . Despite its risk is high in stroke patients, few randomized studies have compared the different prophylactic regimens in these patients. The International Stroke Trial (6) demonstrated a marginally significant reduction in PE using unfractionated heparin (UFH), administered subcutaneously for 2 weeks. However, this effect was only found with medium-dose UFH, and the reduction was not significant with low-dose UFH.
The occurrence of PE was probably underreported in this study, because a population-based study found PE (verified at autopsy) to be the cause of death in 16% of cases (7) . Another multicentre study (8) found that a heparinoid (danaparoid) significantly reduced the frequency of DVT at 3 months, if the drug was administered for 7 days starting within 24 h of the onset of stroke.
Low-dose UFH has been shown to reduce the occurrence of DVT in patients with acute stroke to approximately 20-25% (9, 10) , and has been conventionally regarded as the thromboprophylactic regimen of choice. Preliminary studies (11, 12) have suggested, however, that low-molecularweight heparins (LMWHs) may be as effective as UFH but with fewer haemorrhagic complications, possibly because of greater relative antithrombotic rather than anticoagulant effects (13, 14) . Objectives -To compare the efficacy, safety, and overall risk-benefit profile of enoxaparin and unfractionated heparin (UFH) prophylaxis of venous thromboembolic complications in patients with acute ischaemic stroke. Methods -Patients with ischaemic stroke resulting in lower-limb paralysis lasting for at least 24 h and necessitating bedrest, were randomized within 48 h of the onset of stroke, and treated with enoxaparin (40 mg subcutaneously once daily) or UFH (5000 IU subcutaneously thrice daily) for 10 AE 2 days. Main outcome measures were deep-vein thrombosis, pulmonary embolism (PE), death from any cause, intracranial haemorrhage including haemorrhagic infarction, or any other major bleeding. Results -Outcome events occurred within 3 months of stroke in 40/106 patients treated with enoxaparin (37.7%) and 52/106 patients treated with UFH (49.1%, P ¼ 0.127). Fewer patients treated with enoxaparin (14, 13.2%) than with UFH (20, 18.9%) had evidence of haemorrhagic transformation of ischaemic stroke. Conclusions -Enoxaparin administered subcutaneously once daily was as safe and effective as subcutaneous UFH given thrice daily in the prevention of thromboembolic events in patients with lower limb paralysis caused by acute ischaemic stroke. (15) . In one study, no benefit of LMWH was observed in the prevention of DVT compared with placebo, but thromboprophylaxis was started up to 72 h after the onset of stroke (16) . The LMWH enoxaparin has already been shown to be at least as effective and safe as UFH for prophylaxis of DVT in other high-risk patient groups, such as patients undergoing total hip replacement (17) (18) (19) . Therefore, it was expected that thromboprophylaxis with enoxaparin, administered at the same dose as for major orthopaedic surgery (40 mg once daily), might also be effective and safe in patients with ischaemic stroke. The aim of this study was to compare enoxaparin with UFH in terms of their efficacy and safety for thromboprophylaxis in patients with acute ischaemic stroke. The treatment profiles, defined by a concept of treatment failure encompassing both efficacy and safety criteria, were also compared.
Patients and methods

Patients
Patients of either sex aged 18-90 years with acute ischaemic stroke, defined as acute onset of paralysis lasting for at least 24 h and necessitating bedrest, and a cerebral computed tomography (CT) scan that confirmed the diagnosis of an ischaemic brain infarction, were enrolled from January 1992 to December 1994. Patients were excluded if they were unconscious (Glasgow Coma Scale <9) or immobilized before the onset of stroke; had evidence of either haemorrhagic stroke or stroke thought to be cardio-embolic in origin; had evidence or history of DVT, PE, myocardial infarction or recent neurosurgery (within the last 3 months); history of subarachnoid haemorrhage, gastrointestinal bleeding or active peptic ulceration, hypersensitivity to heparin, LMWH or radio-opaque contrast media, severe heart failure, uncontrolled arterial hypertension, or hepatic or renal impairment, malignant disease, endocarditis, haemorrhagic diathesis, current drug abuse or any clinical condition requiring anticoagulant or antiplatelet therapy. Patients who were pregnant or lactating, who had abnormal blood clotting tests, who had received other investigational medication within the last 3 months, or in whom the study treatment could not be started within 48 h of the onset of the qualifying stroke, were also excluded. Concomitant treatment with anticoagulant or antithrombotic therapy, non-steroidal anti-inflammatory drugs, acetylsalicylic acid (aspirin), other antiplatelet therapy, or any other treatment that may have influenced the interpretation of the study data, was prohibited.
The study was approved by the responsible Ethics Committees and was conducted in accordance with the Declaration of Helsinki (Venice Revision, 1983). Written informed consent was given before entry into the study by all patients or their relatives if the patient was unable to consent.
Study design
This was a multicentre, double-blind, randomized study to compare the relative efficacy and safety of enoxaparin with that of UFH in patients with acute ischaemic stroke. The randomization schedule was prepared in blocks of four by Rhoˆne-Poulenc Rorer, Antony, France (now known as Aventis Pharma) using the program ACR/BIOM/ STAT. In each centre, the investigator-in-charge contacted the study nurse, who issued the treatment packs by numerical order.
Treatments
All study treatments were provided by Rhoˆne-Poulenc Rorer. Enoxaparin was supplied as prefilled syringes containing 40 mg enoxaparin for subcutaneous injection. To maintain the doubleblind nature of the study, prefilled syringes containing isotonic saline (placebo) for subcutaneous injection were also supplied. Unfractionated heparin was supplied as prefilled syringes containing 5000 IU of calcium heparin for subcutaneous injection. All prefilled syringes were of the same volume and contained the same volume of liquid.
Following confirmation of diagnosis and study eligibility and completion of all baseline assessments, and after informed consent, patients were randomized to treatment with either enoxaparin 40 mg once daily followed by two placebo injections at 8-hourly intervals, or UFH 5000 IU three times daily. In the enoxaparin group, the first syringe administered each day always contained the active drug and the second and the third syringes contained placebo. Treatment was started after randomization and within 48 h of the onset of stroke, and continued for 10 AE 2 days or until discharge from hospital, if this was earlier.
Assessments
Patients were examined daily for clinical signs of DVT or PE, neurological deterioration, adverse Enoxaparin for prevention of DVT in stroke events and evidence of injection site haematoma (diameter >5 cm) or overt bleeding (major or minor). Bleeding was classified as major if it was either intracranial or retroperitoneal, associated with a decrease in haemoglobin of at least 20 g/l, or required transfusion of at least 2 units of blood. All other bleeding episodes were defined as minor. In addition, vital signs were measured and walking capability was also assessed.
During the study, unilateral phlebography for DVT, arterial pO 2 measurement and ventilation /perfusion lung scanning for PE, and/or cerebral CT scan, were performed within 24 h when clinically indicated. At day 10 AE 2 (or at final assessment), all patients underwent bilateral ascending phlebography, extended neurological assessment (using both Scandinavian Stroke Study Group and Glasgow Coma Scales) and cerebral CT scan within 24 h of last injection of the study treatment. Venous thrombosis was diagnosed phlebographically by a constant intraluminal filling defect in the deep veins (20) . The results of CT scans were evaluated as intracerebral haemorrhage, intracranial haemorrhage (i.e. haemorrhage other than intracerebral haemorrhage), or haemorrhagic transformation (transformation of an ischaemic infarction without bleeding at the time of enrolment).
Blood samples were taken on day 5 and 10 AE 2 for measurement of haematocrit, haemoglobin, platelet count, creatinine and serum transaminase concentrations.
Patients were followed-up at 3 months to determine their survival status. In the event of death, an autopsy report was obtained whenever possible.
Outcomes and analyses
The main efficacy endpoint was the occurrence of a confirmed thromboembolic event (either DVT or PE) during the treatment period or within 24 h of the last administration of the study treatment. DVT was verified by unilateral or bilateral phlebography, and PE was verified by ventilation/ perfusion lung scanning or pulmonary angiography (a positive finding leading to full dose anticoagulation was found in one of the three suspected cases), or confirmed at autopsy. The occurrence of each event was confirmed by a central independent panel of three radiologists, who remained unaware of the nature of the study treatment.
Safety was evaluated on the basis of local tolerance at the injection site, the occurrence of bleeding complications (either major or minor), changes in haemoglobin, haematocrit or serum transaminase concentrations and the occurrence of thrombocytopenia (at least 50% reduction in platelet count) and adverse events.
In an attempt to evaluate the overall efficacy or safety profile of each treatment, the incidences of failure for the two treatments were compared, either during or at the end of the treatment period (day 10 AE 2). Treatment failure was a composite endpoint, defined as the occurrence of at least one of the following events: phlebographically detected DVT confirmed by central reading; DVT detected at autopsy; clinical signs of PE confirmed by either ventilation/perfusion lung scanning and/or angiography, or detected at autopsy; intracranial haemorrhage (including haemorrhagic infarction) confirmed by central reading of cerebral CT scans; major bleeding complications; and death. Patients were only included in the evaluation if the event(s) occurred within 24 h of the last administration of study drug.
Statistical analyses
Sample size calculations were based on a comparison of rates of treatment failure between the two treatment groups. Assuming a true incidence of treatment failure of 20% in each treatment group (type 1 error of a ¼ 0.05, type 2 error of b ¼ 0.20) (21), a total of 400 evaluable patients (200 per group) were required to show with 80% confidence that enoxaparin was equivalent to UFH, where equivalence was defined as a maximum difference of 10%. The planned recruitment period was 36 months.
Patients were only evaluable if, during the treatment period or within 1 day of the final administration of treatment, the occurrence or non-occurrence of a study endpoint (thromboembolic event, intracranial haemorrhage, major bleeding or death) was confirmed by the central independent panel. The number of patients evaluable for efficacy or overall treatment failure may have differed because of the differences in criteria for each endpoint. All patients who received at least one injection of the study treatments were evaluable for safety.
Fisher's exact (two-tailed) test and 95% confidence intervals (CIs) were used for statistical analyses. Analyses were performed using the statistical program StatXact 4 for the Windows operating system (Cytel Software Corporation, Cambridge, MA, USA).
Results
A total of 212 patients (106 patients per treatment group) were randomized in seven participating centres in Finland, within the planned recruitment period from January 1992 to December 1994. Randomization of the planned 400 patients was not considered practicable within a realistic time period, therefore the study was subsequently terminated. A total of 165 patients, 81/106 (76%) in the enoxaparin group and 84/106 (79%) in the UFH group, were treated for at least 8 days. The majority of premature withdrawals were because of adverse events (Table 1) .
Demographic and baseline characteristics of the two treatment groups were similar (Table 2) . However, there was a higher percentage of patients with obesity and diabetes in the UFH group, whereas alcoholism was more prevalent in the enoxaparin group.
Outcome
Outcome events which occurred during the treatment period and during the 3-month follow-up period are shown in Table 3 (no patients were lost to follow-up). An analysis that took into account all 212 randomized subjects and all observed outcome events showed no statistically significant difference between the two groups. The absolute difference in event rates was 11.3% (95% CI: -1.9 to 24.6%; P ¼ 0.127, Fisher's exact test, twotailed) in favour of the enoxaparin group.
Adverse events
The incidence of adverse events was similar in each treatment group: 81.1% (86/106) of patients treated with enoxaparin and 82.1% (87/106) of patients treated with UFH. However, more patients in the UFH group (17.0%) than the enoxaparin group (8.5%) experienced treatmentrelated adverse events. Bleeding complications, haematoma or haemorrhagic transformation were most commonly reported as treatment-related events. All adverse events reported in more than 5% of patients in any of the treatment groups are listed in Table 4 .
Bleeding complications
Bleeding complications were experienced by 2.8% (3/106) of patients in the enoxaparin group and 1.9% (2/106) of patients in the UFH group. One patient in the enoxaparin group had a major bleeding episode (intracranial haemorrhage), while the remaining four patients had minor bleeding episodes. Transfusion was not required for treatment of bleeding in any patient. Injection-site haematomas (diameter > 5 cm) were observed in 2.8% (3/106) of patients in the enoxaparin group and 3.8% (4/106) of patients in the UFH group. Values are given as n (%). * Deaths, deep-vein thrombosis, pulmonary embolism, major bleeding, or need for other treatment because of aggravation of the condition. 
Values are given as n (%). DVT, Deep-vein thrombosis, TIA, transient ischaemic attacks. * Data are given as mean (standard deviation). Values are given as n (%). DVT, Deep-vein thrombosis; PE, pulmonary embolism. * Three DVTs in the unfractionated heparin group were detected at autopsy (two after the study period). All DVTs in the enoxaparin group were detected by phlebography (three after the study period).
Refers to haemorrhagic transformation of the brain infarction.
Cerebral computed tomography scan evaluation
Cerebral CT scan evaluation was performed within 24 h of the final administration of treatment in 81 patients in the enoxaparin group and 86 patients in the UFH group. Haemorrhagic transformation was detected in 17.3% of patients in the enoxaparin group and 23.3% of patients in the UFH group. One patient in the enoxaparin group also had evidence of intracerebral haemorrhage. The absolute difference in event rates between the two groups was 6.0% (95% CI: )6.1 to 18.1%). Two patients in the enoxaparin group and three patients in the UFH group had symptomatic haemorrhagic transformations with evidence of neurological deterioration before confirmation of haemorrhagic transformation by cerebral CT scan.
Laboratory evaluations
Changes in haemoglobin and serum transaminase concentrations were more common in the UFH group than in the enoxaparin group (7.5% vs 0.9% for haemoglobin, 27.4% vs 15.1% for aspartate aminotransferase, and 36.8% vs 16.0% for alanine aminotransferase, respectively). Five patients treated with UFH and two patients treated with enoxaparin had clinically significant increases in serum transaminase concentrations. No patient developed marked thrombocytopenia during the treatment period.
Deaths
Seventeen patients died during the treatment period, nine (8.5%) in the enoxaparin group and eight (7.5%) patients in the UFH group. Further 32 patients had died by follow-up at 3 months, 12 in the enoxaparin group and 20 patients in the UFH group. Stroke with a preceding neurological deterioration was stated as the cause of 16/17 deaths during the study, and 22/32 deaths during follow-up. Autopsies were carried out on 14 patients, nine patients of whom died during the treatment period and five who died during follow-up. Of the patients who died during the treatment period, two patients in the UFH group and one in the enoxaparin group had PE as an additional cause of death, and one patient in the enoxaparin group had a haemorrhagic cerebral infarction. Of the five patients with autopsy who died during follow-up, an autopsy confirmed PE in one patient treated with enoxaparin and in two patients treated with UFH.
The survival rate at 3 months was higher in the enoxaparin group than in the UFH group (80.2% vs 73.6%), but the difference was not statistically significant (difference in survival rate; 6.6%, 95% CI: )4.7 to 17.9%). None of the 212 patients were lost to follow-up.
Thromboembolic event rate
Overall, 64 patients were excluded from the efficacy analysis, 30 (28%) in the enoxaparin group and 34 (32%) in the UFH group. The most common reason for exclusion was the absence of phlebography (18% of patients in the enoxaparin group and 25% of patients in the UFH group) (Fig. 1) . Data from 148 patients, 76 in the enoxaparin group and 72 in the UFH group, could be evaluated for efficacy. Values are given as n (%). * Patient may have had more than one adverse event. Thromboembolic events (DVT or PE) were confirmed in 19.7% (15/76) of patients in the enoxaparin group and 34.7% (25/72) of patients in the UFH group. The absolute difference in the event rate between the two groups was 15.0% (95% CI: 0.8 to 29.2%; P ¼ 0.044, Fisher's exact test), as shown in Table 5 . Thus, enoxaparin was significantly more effective than UFH in the prevention of thromboembolic events.
DVT was confirmed in 38 patients: 14 patients in the enoxaparin group and 24 patients in the UFH group, with one patient in the enoxaparin group also suffering a fatal PE. Except for one patient in the UFH group who had DVT and a fatal PE, all other DVTs were detected by phlebography. Four patients with confirmed DVT were symptomatic: one patient in the enoxaparin group and three in the UFH group. Proximal DVT was confirmed in six patients: two patients in the enoxaparin group and four in the UFH group. Four of these patients also had a distal DVT: one patient in the enoxaparin group and three in the UFH group. There was close correlation between the side of the body where the DVT was located and the location of paralysis.
PE was confirmed in four patients: one patient in the enoxaparin group and three in the UFH group. In three patients, PE was confirmed at autopsy. One patient in the UFH group was symptomatic of PE. The diagnosis of PE was confirmed by ventilation/perfusion lung scanning on day 7, and the patient was treated with full-dose anticoagulation.
Rate of treatment failure
Treatment failure was a composite endpoint defined as the occurrence of confirmed thromboembolic events (DVT or PE), intracranial haemorrhage including haemorrhagic transformation, major bleeding complications or death. Seventeen patients who were excluded from the efficacy analysis because of the absence of a phlebography, were included in the overall analysis of treatment failure as a result of death or the presence of another endpoint confirmed by cerebral CT scan. Further seven patients included in the efficacy analysis (confirmed absence of thromboembolic events) were excluded from the overall analysis because of the absence of a final cerebral CT scan. A total of 158 patients, 80 in the enoxaparin group and 78 in the UFH group, were included in the analysis of treatment failure.
Treatment failure was confirmed in 38.8% (31/80) of patients in the enoxaparin group and 51.3% (40/78) of patients in the UFH group. The difference in failure rates between the two groups was 12.5% (95% CI: )0.27 to 27.9%; P ¼ 0.150, Fisher's exact test, two-tailed) (Table 6 ). Thus, no statistically significant difference could be seen in the comparison of overall rate of treatment failure for enoxaparin and UFH.
Discussion
To our knowledge, this is the only large, randomized, double-blind study that has compared the efficacy and safety of a LMWH, enoxaparin, with UFH as thromboprophylaxis for patients with acute ischaemic stroke. An analysis that took into account all the 212 randomized subjects and all outcome events showed no statistically significant difference between the two groups, but enoxaparin was more effective than UFH in the prevention of thromboembolic events. Enoxaparin (40 mg s.c. once daily) was equally safe and as effective as UFH (5000 IU s.c. thrice daily) for the prevention of thromboembolic complications in patients with ischaemic stroke.
In the present study, bilateral phlebography was used to detect DVT at day 10 AE 2 (or the end of treatment) with diagnosis confirmed by independent blinded review. As the majority of DVTs are clinically asymptomatic (22) , invasive and Values are given as n (%). DVT, Deep-vein thrombosis; PE, pulmonary embolism. * P ¼ 0.044. One patient in each category also had a confirmed DVT. I-fibrinogen leg scanning, which has been used in previous studies of ischaemic stroke (11, (23) (24) (25) . The incidence of DVT following prophylaxis with UFH was similar using both approaches (33.3% in this study and up to 31.0% using 125 I-fibrinogen leg scanning) (23) , confirming that the prevention of thromboembolic events with UFH is clinically unsatisfactory.
Our results indicate that thromboprophylaxis with enoxaparin is at least as safe as that with UFH. As in a previous study (23) , few patients treated with either enoxaparin or UFH developed bleeding complications. Haemorrhagic transformation of cerebral infarction was observed in fewer patients treated with enoxaparin than in those treated with UFH (17.5% vs 25.6%, absolute difference 8.1%, relative risk reduction 32%). The incidence of haemorrhagic transformation in the present study was lower than that of patients who received a placebo in the European Cooperative Acute Stroke studies (26, 27) , which suggests that both enoxaparin and UFH were safe with regard to haemorrhagic transformation. The only major bleeding complication observed (a cerebral haemorrhage in a patient treated with enoxaparin) was not unexpected because placebo-controlled studies in acute ischaemic stroke have demonstrated an incidence of intracerebral bleeding of about 2% (15, 28) . In contrast, a previous study (23) , showed a higher rate of haemorrhagic transformations in thromboprophylaxis with another LMWH, ORG 10172, than with UFH (9.3% vs 5.6%). These data suggest that the overall risk-benefit profile of the individual LMWHs may differ, and that results for one LMWH should not be extrapolated to all LMWHs.
To evaluate the overall profile of the two thromboprophylactic regimens, the rates of treatment failure (based on both efficacy and safety criteria) were compared. This analysis showed a lower treatment failure rate with enoxaparin than with UFH (38.8% vs 51.3%), but the result was not statistically significant. Moreover, despite similarities in the risk profile of each treatment group, fewer patients in the enoxaparin group died during the 3-month follow-up period than in the UFH group. On further analysis, there was a higher rate of fatal PE during follow-up in the UFH group than in the enoxaparin group (four vs two deaths), as well as one non-fatal PE in the UFH group.
It is possible that calculations of the rate of thromboembolic events and treatment failure were biased by the exclusion of up to 32% of patients from these analyses. Therefore, the results do not indicate that enoxaparin is superior to UFH. In studies of similar design, the number of patients who were evaluable for efficacy analysis varied from 59 to 84%, demonstrating the difficulty of finding patients for complete evaluation (29) (30) (31) (32) (33) . The fact that autopsy was not performed in all patients who died may also introduce bias by underestimating the actual number of DVTs and PEs. The fact that we were able to follow-up all our patients for 3 months is a strength of the present study.
The findings of this study are consistent with those of larger studies in other high-risk patient groups (34) . In studies of patients undergoing hip surgery (17) (18) (19) and other major orthopaedic surgery (35) (36) (37) , prophylaxis with enoxaparin resulted in a substantially lower incidence of thromboembolic events than with UFH. Moreover, meta-analyses have confirmed the significant superiority of LMWH over UFH in the prevention of DVT (38) (39) (40) .
Thromboprophylaxis with enoxaparin offers several practical advantages over UFH in terms of ease of administration, prolonged anticoagulation (which obviates the need for daily monitoring) and a lower risk of immunosensitization and thrombocytopenia (41, 42) . In selected patients, treatment with enoxaparin may also be more costeffective (43) .
This study showed that 40 mg enoxaparin once daily is equally effective as UFH in the prevention of thromboembolic complications in patients with lower-limb paralysis resulting from acute ischaemic stroke. The overall efficacy and safety profile of enoxaparin was more favourable than that of UFH, suggesting that enoxaparin may be a better therapeutic choice for thromboprophylaxis in this high-risk patient group.
